Latest Share Rights Issuance News

Nexalis Therapeutics has issued share rights to directors in lieu of fees, with vesting contingent on successful Phase 2 clinical trial completion, aiming to conserve cash for ongoing drug development.

L1 Group Limited has completed the audit of First Maven Pty Ltd’s FY25 financials and released the merged pro forma results combining Platinum Asset Management and L1 Capital. The merged entity reports $305 million in revenue and $177 million in adjusted EBIT, reflecting key merger adjustments and a complex reverse acquisition structure.